These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26237758)

  • 1. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia.
    Battaggia A; Donzelli A; Font M
    Ann Intern Med; 2015 Aug; 163(3):241-2. PubMed ID: 26237758
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia.
    Cornell JE; Mulrow CD
    Ann Intern Med; 2015 Aug; 163(3):242-3. PubMed ID: 26237759
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia.
    Liakos A; Athanasiadou E; Mainou M; Bekiari E; Haidich AB; Rizos EC; Tsapas A
    Ann Intern Med; 2015 Aug; 163(3):241. PubMed ID: 26237757
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
    Navarese EP; Kolodziejczak M; Schulze V; Gurbel PA; Tantry U; Lin Y; Brockmeyer M; Kandzari DE; Kubica JM; D'Agostino RB; Kubica J; Volpe M; Agewall S; Kereiakes DJ; Kelm M
    Ann Intern Med; 2015 Jul; 163(1):40-51. PubMed ID: 25915661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies are shown to be safe and effective in patients with dyslipidaemia.
    Wise J
    BMJ; 2015 Apr; 350():h2251. PubMed ID: 25921417
    [No Abstract]   [Full Text] [Related]  

  • 6. PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?
    Cainzos-Achirica M; Martin SS; Cornell JE; Mulrow CD; Guallar E
    Ann Intern Med; 2015 Jul; 163(1):64-5. PubMed ID: 25915768
    [No Abstract]   [Full Text] [Related]  

  • 7. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
    Tice JA; Kazi DS; Pearson SD
    JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.
    Li C; Lin L; Zhang W; Zhou L; Wang H; Luo X; Luo H; Cai Y; Zeng C
    J Am Heart Assoc; 2015 Jun; 4(6):e001937. PubMed ID: 26077586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.
    Koren MJ; Scott R; Kim JB; Knusel B; Liu T; Lei L; Bolognese M; Wasserman SM
    Lancet; 2012 Dec; 380(9858):1995-2006. PubMed ID: 23141812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A; Demir K; Altunkeser BB
    Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9 antibodies for the treatment of hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Nutrients; 2014 Dec; 6(12):5517-33. PubMed ID: 25470376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finding the Right Price for Improving Care.
    Charlton B
    JAMA Intern Med; 2016 Jan; 176(1):109. PubMed ID: 26662340
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting PCSK9 for therapeutic gains.
    Shapiro MD; Fazio S; Tavori H
    Curr Atheroscler Rep; 2015 Apr; 17(4):499. PubMed ID: 25712137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of monoclonal antibodies for proprotein convertase subtilisin kexin type 9 inhibition: issues with efficacy, tolerability and safety.
    Das G; Rees A
    Curr Opin Lipidol; 2014 Feb; 25(1):96-8. PubMed ID: 24398451
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 antibodies: A new class of lipid-lowering drugs.
    Gouni-Berthold I
    Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.
    White CM
    Ann Pharmacother; 2015 Dec; 49(12):1327-35. PubMed ID: 26424774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.